Effects of Benralizumab and Tezepelumab in severe asthma
Research type
Research Study
Full title
Analysis of how the antibody treatments, Benralizumab and Tezepelumab, work in severe asthma participants: PRISM 2 study
IRAS ID
354503
Contact name
Kian Fan Chung
Contact email
Sponsor organisation
Imperial College London
Duration of Study in the UK
1 years, 11 months, 21 days
Research summary
This is an observational and laboratory-based study of patients suffering from severe asthma and who have been selected for a newly-available treatment with antibody medicines, one called Benralizumab and another Tezepelumab. These treatments are self-injected every month. Our study will be focused on understanding how these treatments work to reduce the number of attacks of asthma and relieve the narrowing of the airway tubes.
We intend to recruit 12 such patients undergoing these treatments for each antibody from the Royal Brompton Hospital Severe Asthma clinic.. They will be followed up for 7-8 months. They will attend the research centre for 3 times over a 6-8 month period, and at each visit, we will assess their asthma using questionnaires and measurements relating to their asthma. They will have samples of blood, urine, sputum and brushings of the nose taken before and at 1 and 6 months after starting antibody treatment. In addition, they will undergo a fiberoptic bronchoscopy test in order to obtain samples of the airway tube lining and of the airway wall.
All these samples will be analysed regarding the genes and proteins present, and any shifts in these genes or proteins will be related with any improvement in the asthma. In this way, we may obtain a better understanding of how these antibody treatments work, while at the same time we will be able to describe better the type of asthma that the individual asthmatic is suffering from. Therefore, we will be able to determine potentially improved treatments for severe asthma in the future.REC name
Wales REC 4
REC reference
25/WA/0146
Date of REC Opinion
25 Jun 2025
REC opinion
Further Information Favourable Opinion